Clinical Trial Update: A Phase 1 Study of [225Ac]-FPI-1434 Injection [Phase 1]

View source ↗

Summary

A Phase 1 study of [225Ac]-FPI-1434 injection sponsored by Fusion Pharmaceuticals has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenocortical Carcinoma
• Breast Cancer
• Cervical Cancer
• Endometrial Cancer
• Head and Neck Squamous Cell Carcinoma
• Ovarian Cancer
• Triple-negative Breast Cancer
• Uveal Melanoma

Drugs mentioned

• [225Ac]-FPI-1434 injection

Snippet

Sponsor: Fusion Pharmaceuticals Inc. | Conditions: Advanced Solid Tumours, Endometrial Cancer | Phase 1 | Status: TERMINATED